Results 61 to 70 of about 1,704,994 (242)

Psychedelic‐assisted treatment for substance use disorder: A narrative systematic review

Addiction, EarlyView.
Abstract Background and aims This is the first systematic review of the extant literature on all major psychedelic‐assisted treatment for alcohol use disorder (AUD), tobacco use disorder (TUD) and other substance use disorders (SUD). We aimed to summarise the evidence for efficacy of psychedelic‐assisted treatment for AUD, TUD, and SUD; to evaluate its
Theodore Piper, Francesca Small, Sam Brown, Michael Kelleher, Luke Mitcheson, James Rucker, Allan H. Young, John Marsden   +7 more
wiley   +1 more source

The psychoactive effects of repeated ketamine infusions and their mechanistic role in the treatment of alcohol use disorder: Secondary analysis of a randomised controlled trial

Addiction, EarlyView.
Abstract Background and aims Ketamine assisted psychotherapy is a promising new treatment for alcohol use disorder (AUD). The psychoactive effects of repeated intravenous (IV) ketamine infusions in people with AUD and their mechanistic role in treating AUD are largely unknown.
Cassie Bloy, Ananya Sarma, Bethan Marsh, Lorna Hardy, Meryem Grabski, Merve Mollaahmetoglu, Joshua Shotton, Shamhethan Bhaskaran, Anne Lingford‐Hughes, H. Val Curran, Celia Morgan, Will Lawn   +11 more
wiley   +1 more source

Theorizing causality: A qualitative study of xylazine‐related wound diversity and perceived etiology among people who inject drugs

Addiction, EarlyView.
Abstract Background and aims Incidence and severity of opioid‐associated skin and soft‐tissue infections, often requiring intensive and costly medical care, have increased substantially since the emergence of xylazine in the US drug supply. Although progress has been made in clinical and harm reduction recommendations for treating xylazine‐related ...
Danielle German, Kelci Villarroel, Meredith Denney, Adrian Guta, Julie Evans, Jason Bienert, Alex Fidler, Kim Ashburn, Zach Kosinski, Becky L. Genberg   +9 more
wiley   +1 more source

Subtyping patients with heroin addiction at treatment entry: factor derived from the Self-Report Symptom Inventory (SCL-90)

Annals of General Psychiatry, 2010
Background Addiction is a relapsing chronic condition in which psychiatric phenomena play a crucial role. Psychopathological symptoms in patients with heroin addiction are generally considered to be part of the drug addict's personality, or else to be ...
Maremmani Icro, Pani Pier, Pacini Matteo, Bizzarri Jacopo V, Trogu Emanuela, Maremmani Angelo GI, Gerra Gilberto, Perugi Giulio, Dell'Osso Liliana   +8 more
doaj   +1 more source

Neural correlates of adherence to extended-release naltrexone pharmacotherapy in heroin dependence

Translational Psychiatry, 2015
Injectable extended-release naltrexone (XRNTX) presents an effective therapeutic strategy for opioid addiction, however its utility could be hampered by poor adherence.
An-Li Wang, I. Elman, S. Lowen, S. Blady, K. G. Lynch, Hyatt Jm, Charles P. O'Brien, D. Langleben   +7 more
semanticscholar   +1 more source

Temporal and geographical patterns of nitazene detections in drug samples and biospecimens in the United States, 2019–2024

Addiction, EarlyView.
Abstract Background and aims Nitazenes are a novel subclass of synthetic opioids that have been increasingly implicated in the United States (US) overdose crisis. Despite their growing presence in the illicit drug supply, national trends have not been systematically evaluated.
David T. Zhu, Nicole D. Fitzgerald, Joseph J. Palamar, Alex J. Krotulski   +3 more
wiley   +1 more source

Regional perspectives: Substance use related problems in Ethiopia

Addiction, EarlyView.
Abstract Ethiopia, with a population exceeding 130 million, presents a complex landscape for understanding substance use disorders. The country's diverse cultural heritage, varying regional practices, and evolving socioeconomic conditions create unique factors of substance use that differ markedly from global trends.
Tesfa M. Yimer, Wubalem Fekadu, Janni Leung, Awoke Mihretu, Solomon Teferra   +4 more
wiley   +1 more source

What anabolic–androgenic steroids reveal about the limits of current harm reduction models

Addiction, EarlyView.
Abstract Background Harm reduction has largely been shaped by responses to psychoactive drug use where the most urgent harms are acute. These models focus on overdose, blood‐borne viruses, and rapid‐onset toxicity related harms. When applied wholesale to anabolic–androgenic steroids (AAS), they obscure the distinctive pharmacology, consumer typologies,
Timothy Piatkowski, Jason M. Nagata, Suzanne Nielsen   +2 more
wiley   +1 more source

High temporal resolution monitoring of illicit drug consumption across England via wastewater analysis

Addiction, EarlyView.
Abstract Aim To monitor community‐level consumption of 20 illicit drugs across urban areas of England using wastewater‐based epidemiology (WBE) surveillance at high temporal resolution. Design, setting, cases This study was conducted over a 12‐month period in 2022 sampling 24‐hour composite wastewater samples at 15 wastewater treatment plants (WWTPs ...
Helena Rapp‐Wright, Keng Tiong Ng, Derryn Grant, William Francis, Margarita White, Dimitris Evangelopoulos, Yuxing Liu, Konstantina Dimakopoulou, Sofia Zafeiratou, Dylan Wood, Chryshanthi Christy, Stav Friedman, Timothy W. Gant, Klea Katsouyanni, Leon P. Barron   +14 more
wiley   +1 more source

The evolution of Australian cannabis policies, 1967 to 2024

Addiction, EarlyView.
Abstract Aim To describe the outcomes of cannabis policy debates in Australia from 1967 to 2024. Methods We searched popular media, public reports, parliamentary inquiries and policy documents on cannabis in Australia since the 1960s and examined peer reviewed papers, national survey data and police records of cannabis‐related arrests.
Wayne D. Hall, Danielle Dawson, Ben Johnson, Tesfa M. Yimer   +3 more
wiley   +1 more source